

Inventor(s): Darrell R. Anderson et al.  
 Appln. No.: 09 383,916  
 Series Code  $\uparrow$  Serial No.  $\uparrow$

Group Art Unit: 1644  
 Examiner: P. Gambel  
 Atty. Dkt. P 0275716

Appln. Title: Human B7.1-Specific Primatized  
 Antibodies and Transfectomas  
 Expressing Said Antibodies

Filed: August 26, 1999

Hon. Commissioner of Patents  
 Washington, D.C. 20231

Sir:

**REPLY/AMENDMENT/LETTER**

Date: May 29, 2001

TELEPHONE CENTER 1600/2900

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED**

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input checked="" type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously For B & C See <b>Required Separate Paper</b> (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims		20	**minus 20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		1	***minus 3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) .....					add	+ \$270/\$135 =	+ \$0 104/204
5. Original due Date: May 27, 2001		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =				115/215
		(2 mos)	\$390/\$195 =		+ \$0		116/216
		(3 mos)	\$890/\$445 =				117/217
		(Usable only for $\leq$ 2mo.OA --- 4 mos)	\$1390/\$695=				118/218
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1890/\$945=				128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee Attached					+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), .....					+ \$180	+ \$0	126
or if Rule 97(d) Request .....					+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r) .....					+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....					x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE) .....					+ \$710/355	+ \$0	1179/1279
14. Petition fee for .....					+ \$0		
15. TOTAL FEE ENCLOSED =					\$0		

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275716  
 C# M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
 Intellectual Property Group

By Atty: Robin L. Teskin

Sig:


Reg. No. 35,030

Fax: (202) 822-0944

Tel: (202) 861-3623

1100 New York Avenue, NW  
 Ninth Floor  
 Washington, DC 20005-3918  
 Tel: (202) 861-3000  
 Atty/Sec: RLT/kmh

**NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments**



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 31 2001

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application No. 09/383,916

Examiner: P. Gambel

Filed: August 26, 1999

Title: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS EXPRESSING SAID ANTIBODIES

TECH CENTER 1600/2900

#10/C

Harry  
June 1, 2001

\* \* \* \* \*

REPLY AND AMENDMENTS PURSUANT TO 37 C.F.R. §1.111

Hon. Commissioner of Patents  
Washington, D.C. 20231

8/1/01 20h-  
905-2600

Sir:

In response to the Office Action [Non-Final Rejection] dated February 27, 2001, please amend the above-identified application as follows.

IN THE TITLE:

Please cancel the current title and insert the following new title: ~~A~~ TREATMENT OF

F C3

~~AUTOMMUNE DISEASES INCLUDING PSORIASIS USING ANTI-B7.1 (CD80) ANTIBODIES~~ A/

IN THE SPECIFICATION:

Page 1, first paragraph under the heading "Cross Reference to Related Applications", please delete the current paragraph and insert the following new paragraph:

~This application is a divisional of Application No. 08/487,550, filed June 7, 1995, now U.S. Patent 6,113,898.~

Please refer to the Appendix attached hereto for the specific changes.

IN THE CLAIMS:

Please cancel currently pending Claim(s) 1 and 16-20 in order to expedite prosecution in favor of the following claims. Please add the following new claims:

85

C